Keywords: gensia, initiates, phase, gp3269, trial, company, inc

Gensia Initiates Phase I GP3269 Trial

Article | 01 July 1996

Print This

US company Gensia Inc has initiated a Phase I clinical trial with its GP3269, a novel adenosine regulating agent which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in